Drug · CHEMBL877
TRANEXAMIC ACID
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. TRANEXAMIC ACID. Drugs and targets, record CHEMBL877. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL877
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
Acide tranexamique, Acido tranexamico, Amcha, CL 65336, CL-65336, CL65336, Cyclo-f, Cyclocapron, Cyclokapron, Espercil, Femstrual, Haematrix, LB-1148, LB1148, NSC-291305, RP-18429, Rikavarin, TRANS AMCHA, TRANS-AMCHA, Transamin
- ChEMBL
- Open Targets' highest stage
- Approval, for 4 of its 88 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PLG | Plasminogen | Plasminogen inhibitor | INHIBITOR | https://conductscience.org/library/genes/5340 |
Source ChEMBL
Diseases88
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 88Source Open Targets
See all 88 diseasesTrials707
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03364491 | Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean | Phase 3 | 11,000 | 2023-01-19 | tranexamic acid | Its name | ClinicalTrials.gov |
| NCT04733157 | The Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Caesarean Section | Phase 3 | 1,226 | 2023-03-20 | tranexamic acid | Its name | ClinicalTrials.gov |
| NCT01990768 | Prehospital Tranexamic Acid Use for Traumatic Brain Injury | Phase 2 | 967 | 2019-01-14 | tranexamic acid | Its name | ClinicalTrials.gov |
| NCT01998438 | Prospective Trial of Tranexamic Acid in Cardiac Surgery | Phase 4 | 955 | 2016-02-26 | tranexamic acid | Its name | ClinicalTrials.gov |
| NCT02086500 | Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial (STAAMP Trial) | Phase 3 | 903 | 2020-09-10 | tranexamic acid | Its name | ClinicalTrials.gov |
| NCT00113568 | Safety Study of XP12B in Women With Menorrhagia | Phase 3 | 784 | 2010-01-20 | tranexamic acid | Its name | ClinicalTrials.gov |
| NCT01895101 | The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients | Phase 4 | 750 | 2015-04-10 | tranexamic acid | Its name | ClinicalTrials.gov |
| NCT01940523 | Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical | Phase 4 | 640 | 2017-06-14 | tranexamic acid | Its name | ClinicalTrials.gov |
| NCT03136445 | TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia | Phase 3 | 616 | 2025-10-28 | tranexamic acid | Its name | ClinicalTrials.gov |
| NCT03463993 | Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section | Phase 3 | 506 | 2022-04-20 | tranexamic acid | Its name | ClinicalTrials.gov |
1 to 10 of 707
See all 707 trialsComparisons in its trials253
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tranexamic Acid vs Placebo: deaths from any cause | 26 of 5,529 | 32 of 5,471 | 11,000 | NCT03364491 | Trial comparisons |
| Tranexamic Acid vs Placebo: serious adverse events | 82 of 5,529 | 70 of 5,471 | 11,000 | NCT03364491 | Trial comparisons |
| Tranexamic Acid vs Placebo: Number of Participants With Maternal Death or Transfusion of Packed Red Blood Cells | 201 of 5,525 | 233 of 5,470 | 10,995 | NCT03364491 | Trial comparisons |
| Tranexamic Acid vs Placebo: Number of Participants Who Received Open Label TXA or Other Antifibrinolytic | 108 of 5,525 | 109 of 5,470 | 10,995 | NCT03364491 | Trial comparisons |
| Tranexamic Acid vs Placebo: Number of Participants Who Were Transfused With 4 or More Units of Packed Red Blood Cells | 20 of 5,525 | 19 of 5,470 | 10,995 | NCT03364491 | Trial comparisons |
| Tranexamic Acid vs Placebo: Number of Participants Who Were Transfused With Other Blood Products | 29 of 5,525 | 31 of 5,470 | 10,995 | NCT03364491 | Trial comparisons |
| Tranexamic Acid vs Placebo: Number of Participants Who Were Treated With Uterotonics Other Than Oxytocin | 649 of 5,525 | 732 of 5,470 | 10,995 | NCT03364491 | Trial comparisons |
| Tranexamic Acid vs Placebo: Number of Participants Who Received Treatments and Interventions in Response to Bleeding and Related Complications | 892 of 5,525 | 986 of 5,470 | 10,995 | NCT03364491 | Trial comparisons |
| Tranexamic Acid vs Placebo: Number of Participants Who Received Surgical or Radiologic Interventions to Control Bleeding and Related Complications | 233 of 5,525 | 231 of 5,470 | 10,995 | NCT03364491 | Trial comparisons |
| Tranexamic Acid vs Placebo: Number of Participants With Postpartum Infectious Complications | 162 of 5,080 | 125 of 5,009 | 10,089 | NCT03364491 | Trial comparisons |
1 to 10 of 253
See all 253 comparisons in its trialsPapers from its trials465
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Digit Span Test | 1 | 0 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL877
GET https://conductscience.org/api/drugs/v1/CHEMBL877/diseases?page=2